Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes
Lundbeck, the Danish drugmaker, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion, centering the deal around Longboard's promising experimental brain medicine, bexicaserin. This medicine is in late-stage clinical testing for treating developmental and epileptic
The approval of Bluebird bio's gene therapy, Skysona, in September 2022 by the FDA marked a significant milestone for treating cerebral adrenoleukodystrophy (CALD), a rare and fatal childhood brain disorder. Skysona's innovation generated hope for families dealing with CALD, yet recent
In a dynamic twist within the pharmaceutical industry, several companies are locked in a fierce race to develop the next generation of obesity drugs. As the battle heats up, each aims to outdo the other, with innovations that promise to revolutionize the way obesity is treated. This race isn't
The biopharmaceutical industry is rapidly evolving, fueled by cutting-edge technologies and scientific breakthroughs. Novel treatments such as cell and gene therapies, biologics, and vaccines are reaching the market at unprecedented speeds. However, the rigorous journey from drug development to
The controversy surrounding Cassava Sciences and its experimental Alzheimer's drug, simufilam, has garnered significant attention within the medical and research communities, as well as among regulatory bodies and patient advocacy groups. Allegations of data manipulation and scientific